Somatostatin-based therapies for external gastrointestinal fistulas: Updated meta-analysis of randomized clinical trials
Somatostatin-based therapies did not significantly improve fistula closure rates but were associated with shorter time to closure and hospital stay. Mortality, complications, and surgical intervention requirements remained unchanged, suggesting that these therapies may serve only as an adjunctive option in selected patients.
Authors
- Rafael Dib Possiedi (ORCID: https://orcid.org/0000-0002-3678-7920)
- Lucas Fontenelle Vieira (ORCID: https://orcid.org/0000-0002-3544-1100)
- Adil Baig
- Marcelo Augusto Fontenelle Ribeiro (ORCID: https://orcid.org/0000-0001-9826-4722)
- Hisham Mohammed (ORCID: https://orcid.org/0000-0003-1201-4736)
- Suhaizal Hashim (ORCID: https://orcid.org/0000-0002-0236-1892)
- A Khan
- Husna Irfan Thalib (ORCID: https://orcid.org/0009-0009-6361-6586)
- Syed Fouzaan Albeez
- Faaleha Heba Fakruddin
Institutions
- University of Maryland, Baltimore (US)
- University of Maryland Medical Center (US)
- Universidade de Sorocaba (BR)
- King Abdullah Medical City (SA)
- Florida Atlantic University (US)
Publication Details
- Journal
- World Journal of Gastrointestinal Pharmacology and Therapeutics
- Published
- 2025-12-05
- DOI
- https://doi.org/10.4292/wjgpt.v16.i4.111889
- Primary Topic
- Abdominal Surgery and Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00